Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.95 |
| ▸ | ARG2 | P78540 | 4/20 | 0.57 |
| ▸ | ARG1 | P05089 | 3/20 | 0.57 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | NOS1 | P29475 | 3/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL16683 | 1.00 | GSR (0.95) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL8201285 | 1.00 | GSR (0.95) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL23608089 | 0.98 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL29676956 | 0.98 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL12496887 | 0.98 | GSR (0.91) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL1645 | 0.98 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL7343 | 0.98 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL456381 | 0.98 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL12867528 | 0.98 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 | |
| Lysine SCHEMBL20362357 | 0.98 | GSR (1.00) | GSRARG2ARG1RNPEPNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 548 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332107-A1 | IMMEDIATE RELEASE DOSAGE FORM | KENVUE BRANDS LLC (US) | 2025-10-30 | — | — | US | claimed |
| CN-120058564-A | Method and device for producing pentanediol | 摩珈(上海)生物科技有限公司 | 2025-05-30 | — | — | CN | claimed |
| US-12296049-B2 | Immediate release dosage form | KENVUE BRANDS LLC (US) | 2025-05-13 | — | — | US | claimed |
| WO-2025040153-A1 | METHOD FOR PREPARING ISOCYANATE AND DEVICE | 摩珈(上海)生物科技有限公司 | 2025-02-27 | — | — | WO | claimed |
| EP-4473962-A2 | IMMEDIATE RELEASE DOSAGE FORM | Johnson & Johnson Consumer Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| EP-3781136-B1 | IMMEDIATE RELEASE DOSAGE FORM | JOHNSON & JOHNSON CONSUMER INC (US) | 2024-09-25 | — | — | EP | claimed |
| US-20240180821-A1 | ORALLY DISINTEGRATING FILM COMPOSITION OF KETOROLAC AND A METHOD OF PREPARATION THEREOF | LN LABORATORIES PVT LTD (IN) | 2024-06-06 | — | — | US | claimed |
| US-20230414520-A1 | IMMEDIATE RELEASE DOSAGE FORM | KENVUE BRANDS LLC | 2023-12-28 | — | — | US | claimed |
| CN-108997141-B | Preparation method of 1, 5-pentanediamine | 河北美邦工程科技股份有限公司 | 2021-10-19 | — | — | CN | claimed |
| US-20210307329-A1 | Herbicidal Composition | SUMITOMO CHEMICAL AUSTRALIA PTY LTD (AU) | 2021-10-07 | — | — | US | claimed |
| WO-2005011737-A2 | PHARMACEUTICAL COMBINATIONS AND FORMULATIONS WITH IMPROVED STABILITY | CIPLA LIMITED (IN) | 2005-02-10 | — | — | WO | claimed |
| CN-1578657-A | Process for the preparation of fast dissolving dosage form | LAMBECKSA LAB INC (IN) | 2005-02-09 | — | — | CN | claimed |
| EP-1490024-A1 | EFFERVESCENT COMPOSITIONS COMPRISING BISPHOSPHONATES AND METHODS RELATED THERETO | Lifizz, Inc. (US) | 2004-12-29 | — | — | EP | claimed |
| WO-2003075884-A1 | EFFERVESCENT COMPOSITIONS COMPRISING BISPHOSPHONATES AND METHODS RELATED THERETO | LIFIZZ, INC. (US) | 2003-09-18 | — | — | WO | claimed |
| EP-0954292-A1 | PHARMACEUTICAL FORMULATIONS WITH DELAYED DRUG RELEASE | POLI INDUSTRIA CHIMICA S.p.A. (IT) | 1999-11-10 | — | — | EP | claimed |
| WO-1998032425-A1 | PHARMACEUTICAL FORMULATIONS WITH DELAYED DRUG RELEASE | POLI INDUSTRIA CHIMICA S.P.A. (US) | 1998-07-30 | — | — | WO | claimed |
| EP-0155427-B1 | READY FOR USE, RAPIDLY DISINTEGRATING, SOLID CULTURE MEDIUM, AND PROCESS FOR ITS PREPARATION | SOCIETE D'APPLICATIONS PHARMACEUTIQUES ET BIOLOGIQUES HOECHST-BEHRING (FR) | 1988-05-04 | — | — | EP | claimed |
| EP-0092287-B1 | ACETYLCYSTEINE SALTS, THEIR PREPARATION AND USE | "PHARLYSE", Société Anonyme (LU) | 1987-03-25 | — | — | EP | claimed |
| EP-0078785-B1 | SALTS OF VALPROIC ACID, THEIR PREPARATION AND THEIR USE | "PHARLYSE", Société Anonyme (LU) | 1985-04-03 | — | — | EP | claimed |
| US-3932491-A | Process for optical resolution of racemic lysine sulphanilate | STAMICARBON B.V. (NL) | 1976-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180821-A1 | ORALLY DISINTEGRATING FILM COMPOSITION OF KETOROLAC AND A METHOD OF PREPARATION THEREOF | SI, TREH, SORD | GSR 3887/4885ARG2 2990/4885ARG1 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.